Single-center Experience in Treating Patients With t(4;14) Multiple Myeloma With and Without Planned Frontline Autologous Stem Cell Transplantation

Conclusion Even in the era of novel agents, t(4;14) remains a negative prognostic marker. Frontline autologous stem cell transplant remains as an essential tool when treating these high-risk patients, but further prospective randomized studies are needed to determine the most effective strategy for this patient group. Micro-Abstract This retrospective study analyzed the long-term outcome of 75 patients with t(4;14) multiple myeloma treated in a single center with frontline bortezomib-based treatment. Frontline autologous stem cell transplant following bortezomib-based induction was associated with better progression-free survival. These results further support the use of frontline autologous stem cell transplant, especially among patients with high-risk cytogenetics.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research